참고문헌 (125)

1. 1 Thies W Bleiler L Alzheimer's Association 2013 Alzheimer's disease facts and figures Alzheimers Dement 2013 9 208 245 23507120 

2. 2 Wimo A Winblad B Jönsson L The worldwide societal costs of dementia: estimates for 2009 Alzheimers Dement 2010 6 98 103 20298969 

3. 3 Hardy JA Higgins GA Alzheimer's disease: the amyloid cascade hypothesis Science 1992 256 184 185 1566067 

   상세보기

4. 4 Hardy J Selkoe DJ The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 2002 297 353 356 12130773 

   상세보기

5. 5 Karran E Mercken M De Strooper B The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Nat Rev Drug Discov 2011 10 698 712 21852788 

6. 6 Vassar R Bennett BD Babu-Khan S Kahn S Mendiaz EA Denis P Teplow DB Ross S Amarante P Loeloff R Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE Science 1999 286 735 741 10531052 

7. 7 Wolfe MS Xia W Ostaszewski BL Diehl TS Kimberly WT Selkoe DJ Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity Nature 1999 398 513 517 10206644 

   상세보기

8. 8 De Strooper B Saftig P Craessaerts K Vanderstichele H Guhde G Annaert W Von Figura K Van Leuven F Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein Nature 1998 391 387 390 9450754 

   상세보기

9. 9 Mucke L Neuroscience: Alzheimer's disease Nature 2009 461 895 897 19829367 

   상세보기

10. 10 Shankar GM Li S Mehta TH Garcia-Munoz A Shepardson NE Smith I Brett FM Farrell MA Rowan MJ Lemere CA Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory Nat Med 2008 14 837 842 18568035 

11. 11 Mandelkow EM Mandelkow E Tau in Alzheimer's disease Trends Cell Biol 1998 8 425 427 9854307 

    상세보기

12. 12 Geschwind DH Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron 2003 40 457 460 14642270 

    상세보기

13. 13 Götz J Chen F van Dorpe J Nitsch RM Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils Science 2001 293 1491 1495 11520988 

    상세보기

14. 14 Lewis J Dickson DW Lin WL Chisholm L Corral A Jones G Yen SH Sahara N Skipper L Yager D Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP Science 2001 293 1487 1491 11520987 

    상세보기

15. 15 Ittner LM Ke YD Delerue F Bi M Gladbach A van Eersel J Wölfing H Chieng BC Christie MJ Napier IA Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models Cell 2010 142 387 397 20655099 

16. 16 Buckholtz NS Perspective: in search of biomarkers Nature 2011 475 S8 21760582 

    상세보기

17. 17 Callaway E Alzheimer's drugs take a new tack Nature 2012 489 13 14 22962697 

    상세보기

18. 18 Raskind MA Peskind ER Wessel T Yuan W Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension: the Galantamine USA-1 Study Group Neurology 2000 54 2261 2268 10881250 

19. 19 Van Dyck CH Tariot PN Meyers B Malca Resnick E Memantine MEM-MD-01 Study Group A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease Alzheimer Dis Assoc Disord 2007 21 136 143 17545739 

    상세보기

20. 20 Tariot PN Farlow MR Grossberg GT Graham SM McDonald S Gergel I Memantine Study Group Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial JAMA 2004 291 317 324 14734594 

    상세보기

21. 21 Winblad B Kilander L Eriksson S Minthon L Båtsman S Wetterholm AL Jansson-Blixt C Haglund A Severe Alzheimer's Disease Study Group Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study Lancet 2006 367 1057 1065 16581404 

22. 22 Atri A Shaughnessy LW Locascio JJ Growdon JH Long-term course and effectiveness of combination therapy in Alzheimer disease Alzheimer Dis Assoc Disord 2008 22 209 221 18580597 

    상세보기

23. 23 Lopez OL Becker JT Wahed AS Saxton J Sweet RA Wolk DA Klunk W Dekosky ST Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease J Neurol Neurosurg Psychiatry 2009 80 600 607 19204022 

    상세보기

24. 24 Sabbagh MN Drug development for Alzheimer's disease: where are we now and where are we headed Am J Geriatr Pharmacother 2009 7 167 185 19616185 

25. 25 Froestl W Gallagher M Jenkins H Madrid A Melcher T Teichman S Mondadori CG Pearlman R SGS742: the first GABA(B) receptor antagonist in clinical trials Biochem Pharmacol 2004 68 1479 1487 15451390 

    상세보기

26. 26 Grill JD Cummings JL Current therapeutic targets for the treatment of Alzheimer's disease Expert Rev Neurother 2010 10 711 728 20420492 

27. 27 Potter A Corwin J Lang J Piasecki M Lenox R Newhouse PA Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease Psychopharmacology (Berl) 1999 142 334 342 10229057 

28. 28 Arnt J Bang-Andersen B Grayson B Bymaster FP Cohen MP DeLapp NW Giethlen B Kreilgaard M McKinzie DL Neill JC Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats Int J Neuropsychopharmacol 2010 13 1021 1033 20569520 

    상세보기

29. 29 DeKosky ST Williamson JD Fitzpatrick AL Kronmal RA Ives DG Saxton JA Lopez OL Burke G Carlson MC Fried LP Ginkgo biloba for prevention of dementia: a randomized controlled trial JAMA 2008 300 2253 2262 19017911 

    상세보기

30. 30 Park SJ Jung HJ Son MS Jung JM Kim DH Jung IH Cho YB Lee EH Ryu JH Neuroprotective effects of INM-176 against lipopolysaccharide-induced neuronal injury Pharmacol Biochem Behav 2012 101 427 433 22342662 

    상세보기

31. 31 Shi C Zhao L Zhu B Li Q Yew DT Yao Z Xu J Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptide-induced toxicity in SH-SY5Y cells Chem Biol Interact 2009 181 115 123 19464278 

32. 32 LaFerla FM Green KN Oddo S Intracellular amyloid-beta in Alzheimer's disease Nat Rev Neurosci 2007 8 499 509 17551515 

33. 33 Ghosh AK Gemma S Tang J Beta-Secretase as a therapeutic target for Alzheimer's disease Neurotherapeutics 2008 5 399 408 18625451 

34. 34 Ghosh AK Bilcer G Harwood C Kawahama R Shin D Hussain KA Hong L Loy JA Nguyen C Koelsch G Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase) J Med Chem 2001 44 2865 2868 11520194 

35. 35 Ghosh AK Brindisi M Tang J Developing β-secretase inhibitors for treatment of Alzheimer's disease J Neurochem 2012 120 71 83 22122681 

    상세보기

36. 36 Sisodia SS St George-Hyslop PH Gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 2002 3 281 290 11967558 

    상세보기

37. 37 Louvi A Artavanis-Tsakonas S Notch signalling in vertebrate neural development Nat Rev Neurosci 2006 7 93 102 16429119 

    상세보기

38. 38 Henley DB May PC Dean RA Siemers ER Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease Expert Opin Pharmacother 2009 10 1657 1664 19527190 

    상세보기

39. 39 Walsh DM Selkoe DJ A beta oligomers - a decade of discovery J Neurochem 2007 101 1172 1184 17286590 

40. 40 Glabe CG Structural classification of toxic amyloid oligomers J Biol Chem 2008 283 29639 29643 18723507 

    상세보기

41. 41 Nakagami Y Nishimura S Murasugi T Kaneko I Meguro M Marumoto S Kogen H Koyama K Oda T A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro Br J Pharmacol 2002 137 676 682 12381681 

    상세보기

42. 42 Yang F Lim GP Begum AN Ubeda OJ Simmons MR Ambegaokar SS Chen PP Kayed R Glabe CG Frautschy SA Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J Biol Chem 2005 280 5892 5901 15590663 

    상세보기

43. 43 McKoy AF Chen J Schupbach T Hecht MH A novel inhibitor of amyloid β (Aβ) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease J Biol Chem 2012 287 38992 39000 22992731 

44. 44 Bush AI Drug development based on the metals hypothesis of Alzheimer's disease J Alzheimers Dis 2008 15 223 240 18953111 

45. 45 Faux NG Ritchie CW Gunn A Rembach A Tsatsanis A Bedo J Harrison J Lannfelt L Blennow K Zetterberg H PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses J Alzheimers Dis 2010 20 509 516 20164561 

46. 46 Adlard PA Cherny RA Finkelstein DI Gautier E Robb E Cortes M Volitakis I Liu X Smith JP Perez K Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta Neuron 2008 59 43 55 18614028 

47. 47 Lemere CA Blusztajn JK Yamaguchi H Wisniewski T Saido TC Selkoe DJ Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation Neurobiol Dis 1996 3 16 32 9173910 

48. 48 Saido TC Yamao-Harigaya W Iwatsubo T Kawashima S Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain Neurosci Lett 1996 215 173 176 8899741 

49. 49 Kuo YM Emmerling MR Woods AS Cotter RJ Roher AE Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits Biochem Biophys Res Commun 1997 237 188 191 9266855 

50. 50 Schilling S Appl T Hoffmann T Cynis H Schulz K Jagla W Friedrich D Wermann M Buchholz M Heiser U Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ J Neurochem 2008 106 1225 1236 18627432 

51. 51 Schilling S Hoffmann T Manhart S Hoffmann M Demuth HU Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions FEBS Lett 2004 563 191 196 15063747 

    상세보기

52. 52 Sastre M Klockgether T Heneka MT Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms Int J Dev Neurosci 2006 24 167 176 16472958 

    상세보기

53. 53 Rubio-Perez JM Morillas-Ruiz JM A review: inflammatory process in Alzheimer's disease, role of cytokines ScientificWorldJournal 2012 2012 756357 22566778 

    상세보기

54. 54 Weninger SC Yankner BA Inflammation and Alzheimer disease: the good, the bad, and the ugly Nat Med 2001 7 527 528 11329045 

    상세보기

55. 55 Lambert JC Grenier-Boley B Chouraki V Heath S Zelenika D Fievet N Hannequin D Pasquier F Hanon O Brice A Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis J Alzheimers Dis 2010 20 1107 1118 20413860 

56. 56 Vlad SC Miller DR Kowall NW Felson DT Protective effects of NSAIDs on the development of Alzheimer disease Neurology 2008 70 1672 1677 18458226 

    상세보기

57. 57 Imbimbo BP Solfrizzi V Panza F Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci 2010 2 pii: 19 

58. 58 Szekely CA Breitner JC Fitzpatrick AL Rea TD Psaty BM Kuller LH Zandi PP NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type Neurology 2008 70 17 24 18003940 

    상세보기

59. 59 Szekely CA Thorne JE Zandi PP Ek M Messias E Breitner JC Goodman SN Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review Neuroepidemiology 2004 23 159 169 15279021 

    상세보기

60. 60 Scharf S Mander A Ugoni A Vajda F Christophidis N A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease Neurology 1999 53 197 201 10408559 

    상세보기

61. 61 Reines SA Block GA Morris JC Liu G Nessly ML Lines CR Norman BA Baranak CC Rofecoxib Protocol 091 Study Group Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 2004 62 66 71 14718699 

    상세보기

62. 62 Soininen H West C Robbins J Niculescu L Long-term efficacy and safety of celecoxib in Alzheimer's disease Dement Geriatr Cogn Disord 2007 23 8 21 17068392 

    상세보기

63. 63 De Jong D Jansen R Hoefnagels W Jellesma-Eggenkamp M Verbeek M Borm G Kremer B No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial PLoS One 2008 3 e1475 18213383 

    상세보기

64. 64 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil Phase 3 Study Group Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA 2009 302 2557 2564 20009055 

    상세보기

65. 65 Pasqualetti P Bonomini C Dal Forno G Paulon L Sinforiani E Marra C Zanetti O Rossini PM A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease Aging Clin Exp Res 2009 21 102 110 19448381 

    상세보기

66. 66 Delrieu J Ousset PJ Caillaud C Vellas B 'Clinical trials in Alzheimer's disease': immunotherapy approaches J Neurochem 2012 120 186 193 21883222 

    상세보기

67. 67 Fu HJ Liu B Frost JL Lemere CA Amyloid-beta immunotherapy for Alzheimer's disease CNS Neurol Disord Drug Targets 2010 9 197 206 20205640 

68. 68 Panza F Frisardi V Solfrizzi V Imbimbo BP Logroscino G Santamato A Greco A Seripa D Pilotto A Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies Immunotherapy 2012 4 213 238 22339463 

69. 69 Schenk D Barbour R Dunn W Gordon G Grajeda H Guido T Hu K Huang J Johnson-Wood K Khan K Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 1999 400 173 177 10408445 

    상세보기

70. 70 Das P Howard V Loosbrock N Dickson D Murphy MP Golde TE Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice J Neurosci 2003 23 8532 8538 13679422 

71. 71 Bayer AJ Bullock R Jones RW Wilkinson D Paterson KR Jenkins L Millais SB Donoghue S Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD Neurology 2005 64 94 101 15642910 

    상세보기

72. 72 DeMattos RB Bales KR Cummins DJ Dodart JC Paul SM Holtzman DM Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc Natl Acad Sci U S A 2001 98 8850 8855 11438712 

    상세보기

73. 73 Dodart JC Bales KR Gannon KS Greene SJ DeMattos RB Mathis C DeLong CA Wu S Wu X Holtzman DM Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model Nat Neurosci 2002 5 452 457 11941374 

74. 74 Orgogozo JM Gilman S Dartigues JF Laurent B Puel M Kirby LC Jouanny P Dubois B Eisner L Flitman S Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 2003 61 46 54 12847155 

    상세보기

75. 75 Holmes C Boche D Wilkinson D Yadegarfar G Hopkins V Bayer A Jones RW Bullock R Love S Neal JW Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 2008 372 216 223 18640458 

76. 76 Roberson ED Scearce-Levie K Palop JJ Yan F Cheng IH Wu T Gerstein H Yu GQ Mucke L Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model Science 2007 316 750 754 17478722 

77. 77 Santacruz K Lewis J Spires T Paulson J Kotilinek L Ingelsson M Guimaraes A DeTure M Ramsden M McGowan E Tau suppression in a neurodegenerative mouse model improves memory function Science 2005 309 476 481 16020737 

    상세보기

78. 78 Oddo S Billings L Kesslak JP Cribbs DH LaFerla FM Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome Neuron 2004 43 321 332 15294141 

79. 79 Vogelsberg-Ragaglia V Schuck T Trojanowski JQ Lee VM PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus Exp Neurol 2001 168 402 412 11259128 

    상세보기

80. 80 Sontag E Luangpirom A Hladik C Mudrak I Ogris E Speciale S White CL 3rd Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology J Neuropathol Exp Neurol 2004 63 287 301 15099019 

81. 81 Schneider A Mandelkow E Tau-based treatment strategies in neurodegenerative diseases Neurotherapeutics 2008 5 443 457 18625456 

    상세보기

82. 82 Hampel H Ewers M Bürger K Annas P Mörtberg A Bogstedt A Frölich L Schröder J Schönknecht P Riepe MW Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study J Clin Psychiatry 2009 70 922 931 19573486 

    상세보기

83. 83 Tariot PN Aisen PS Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry 2009 70 919 921 19573485 

84. 84 Arendash GW Mori T Cao C Mamcarz M Runfeldt M Dickson A Rezai-Zadeh K Tane J Citron BA Lin X Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice J Alzheimers Dis 2009 17 661 680 19581722 

85. 85 Noble W Planel E Zehr C Olm V Meyerson J Suleman F Gaynor K Wang L LaFrancois J Feinstein B Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo Proc Natl Acad Sci U S A 2005 102 6990 6995 15867159 

    상세보기

86. 86 Domínguez JM Fuertes A Orozco L del Monte-Millán M Delgado E Medina M Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib J Biol Chem 2012 287 893 904 22102280 

87. 87 Eldar-Finkelman H Martinez A GSK-3 inhibitors: preclinical and clinical focus on CNS Front Mol Neurosci 2011 4 32 22065134 

    상세보기

88. 88 Del Ser T Steinwachs KC Gertz HJ Andrés MV Gómez-Carrillo B Medina M Vericat JA Redondo P Fleet D León T Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study J Alzheimers Dis 2013 33 205 215 22936007 

89. 89 Wischik CM Harrington CR Storey JM Tau-aggregation inhibitor therapy for Alzheimer's disease Biochem Pharmacol 2014 88 529 539 24361915 

    상세보기

90. 90 Pickhardt M Gazova Z von Bergen M Khlistunova I Wang Y Hascher A Mandelkow EM Biernat J Mandelkow E Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells J Biol Chem 2005 280 3628 3635 15525637 

    상세보기

91. 91 Taniguchi S Suzuki N Masuda M Hisanaga S Iwatsubo T Goedert M Hasegawa M Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins J Biol Chem 2005 280 7614 7623 15611092 

    상세보기

92. 92 Crowe A Huang W Ballatore C Johnson RL Hogan AM Huang R Wichterman J McCoy J Huryn D Auld DS Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening Biochemistry 2009 48 7732 7745 19580328 

93. 93 Blass JP Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 2001 66 851 856 11746411 

    상세보기

94. 94 Blass JP Gibson GE Hoyer S The role of the metabolic lesion in Alzheimer's disease J Alzheimers Dis 2002 4 225 232 12226541 

95. 95 Hoyer S Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease: causes and consequences: an update Exp Gerontol 2000 35 1363 1372 11113614 

    상세보기

96. 96 Kurochkin IV Goto S Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme FEBS Lett 1994 345 33 37 8194595 

97. 97 McDermott JR Gibson AM Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme Neurochem Res 1997 22 49 56 9021762 

98. 98 Sudoh S Frosch MP Wolf BA Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells Biochemistry 2002 41 1091 1099 11802707 

99. 99 Farris W Mansourian S Chang Y Lindsley L Eckman EA Frosch MP Eckman CB Tanzi RE Selkoe DJ Guenette S Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo Proc Natl Acad Sci U S A 2003 100 4162 4167 12634421 

    상세보기

100. 100 Vekrellis K Ye Z Qiu WQ Walsh D Hartley D Chesneau V Rosner MR Selkoe DJ Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme J Neurosci 2000 20 1657 1665 10684867 

101. 101 Bosco D Fava A Plastino M Montalcini T Pujia A Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis J Cell Mol Med 2011 15 1807 1821 21435176 

     상세보기

102. 102 Son SM Song H Byun J Park KS Jang HC Park YJ Mook-Jung I Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions Autophagy 2012 8 1842 1844 22931791 

     상세보기

103. 103 Gupta A Bisht B Dey CS Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes Neuropharmacology 2011 60 910 920 21277873 

     상세보기

104. 104 Colca JR McDonald WG Cavey GS Cole SL Holewa DD Brightwell-Conrad AS Wolfe CL Wheeler JS Coulter KR Kilkuskie PM Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT): relationship to newly identified mitochondrial pyruvate carrier proteins PLoS One 2013 8 e61551 23690925 

     상세보기

105. 105 Divakaruni AS Wiley SE Rogers GW Andreyev AY Petrosyan S Loviscach M Wall EA Yadava N Heuck AP Ferrick DA Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier Proc Natl Acad Sci U S A 2013 110 5422 5427 23513224 

     상세보기

106. 106 Hirai K Aliev G Nunomura A Fujioka H Russell RL Atwood CS Johnson AB Kress Y Vinters HV Tabaton M Mitochondrial abnormalities in Alzheimer's disease J Neurosci 2001 21 3017 3023 11312286 

     상세보기

107. 107 Manczak M Anekonda TS Henson E Park BS Quinn J Reddy PH Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression Hum Mol Genet 2006 15 1437 1449 16551656 

108. 108 Caspersen C Wang N Yao J Sosunov A Chen X Lustbader JW Xu HW Stern D McKhann G Yan SD Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease FASEB J 2005 19 2040 2041 16210396 

     상세보기

109. 109 Du H Guo L Yan S Sosunov AA McKhann GM Yan SS Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model Proc Natl Acad Sci U S A 2010 107 18670 18675 20937894 

     상세보기

110. 110 Cha MY Han SH Son SM Hong HS Choi YJ Byun J Mook-Jung I Mitochondria-specific accumulation of amyloid β induces mitochondrial dysfunction leading to apoptotic cell death PLoS One 2012 7 e34929 22514691 

111. 111 Correia SC Santos RX Carvalho C Cardoso S Candeias E Santos MS Oliveira CR Moreira PI Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation Brain Res 2012 1441 64 78 22290178 

     상세보기

112. 112 Valla J Schneider L Niedzielko T Coon KD Caselli R Sabbagh MN Ahern GL Baxter L Alexander G Walker DG Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment Mitochondrion 2006 6 323 330 17123871 

     상세보기

113. 113 Parihar MS Brewer GJ Mitoenergetic failure in Alzheimer disease Am J Physiol Cell Physiol 2007 292 C8 C23 16807300 

     상세보기

114. 114 Swerdlow RH Brain aging, Alzheimer's disease, and mitochondria Biochim Biophys Acta 2011 1812 1630 1639 21920438 

115. 115 Bezprozvanny I The rise and fall of Dimebon Drug News Perspect 2010 23 518 523 21031168 

116. 116 Malykh AG Sadaie MR Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders Drugs 2010 70 287 312 20166767 

117. 117 Leuner K Kurz C Guidetti G Orgogozo JM Müller WE Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam Front Neurosci 2010 4 pii: 44 

118. 118 Calkins MJ Manczak M Mao P Shirendeb U Reddy PH Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease Hum Mol Genet 2011 20 4515 4529 21873260 

     상세보기

119. 119 Chen S Owens GC Makarenkova H Edelman DB HDAC6 regulates mitochondrial transport in hippocampal neurons PLoS One 2010 5 e10848 20520769 

120. 120 Kim C Choi H Jung ES Lee W Oh S Jeon NL Mook-Jung I HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons PLoS One 2012 7 e42983 22937007 

     상세보기

121. 121 Kim C Nam DW Park SY Song H Hong HS Boo JH Jung ES Kim Y Baek JY Kim KS O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment Neurobiol Aging 2013 34 275 285 22503002 

     상세보기

122. 122 Lester-Coll N Rivera EJ Soscia SJ Doiron K Wands JR de la Monte SM Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease J Alzheimers Dis 2006 9 13 33 16627931 

123. 123 Tallent MK Varghis N Skorobogatko Y Hernandez-Cuebas L Whelan K Vocadlo DJ Vosseller K In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation J Biol Chem 2009 284 174 181 19004831 

     상세보기

124. 124 Yuzwa SA Macauley MS Heinonen JE Shan X Dennis RJ He Y Whitworth GE Stubbs KA McEachern EJ Davies GJ A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo Nat Chem Biol 2008 4 483 490 18587388 

     상세보기

125. 125 Villemagne VL Burnham S Bourgeat P Brown B Ellis KA Salvado O Szoeke C Macaulay SL Martins R Maruff P Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 2013 12 357 367 23477989 

     상세보기